目的 探討平喘抗炎膠囊聯(lián)合沙丁胺醇治療支氣管哮喘的臨床療效。方法 選取2017年6月—2019年12月重慶醫(yī)科大學附屬永川醫(yī)院收治的支氣管哮喘患者140例作為研究對象，根據(jù)隨機數(shù)字表法將患者分為對照組和觀察組，每組各70例。對照組患者經(jīng)口吸入硫酸沙丁胺醇氣霧劑，0.1 mg/次，4次/d。觀察組在對照組患者治療的基礎(chǔ)上口服平喘抗炎膠囊，2粒/次，3次/d。兩組連續(xù)治療8周。比較兩組患者的臨床療效，對比兩組患者的癥狀改善情況、第一秒用力呼氣容積（FEV1）、FEV1預計值、呼氣峰值流速（PEF）、細胞間黏附分子-1（ICAM-1）、血清轉(zhuǎn)化生長因子β1（TGF-β1）和白細胞介素-17（IL-17）水平。結(jié)果 治療后，觀察組患者總有效率為94.29%，明顯高于對照組的82.86%（P<0.05）。治療后，觀察組患者的止咳時間、咯痰消失時間、哮鳴音消失時間顯著短于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。兩組治療后的FEV1、FEV1預計值和PEF水平均明顯升高，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；觀察組治療后的FEV1、FEV1預計值、PEF顯著高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。兩組治療后的ICAM-1、TGF-β1、IL-17均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05），且觀察組治療后氣道炎癥反應(yīng)指標明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 平喘抗炎膠囊聯(lián)合沙丁胺醇治療支氣管哮喘具有較好的臨床療效，可有效降低氣道炎癥反應(yīng)，提高肺功能，具有良好的臨床研究價值。

Objective To explore the clinical effect of Pingchuan Kangyan Capsules combined with salbutamol in treatment of bronchial asthma. Methods A total of 140 patients with bronchial asthma in Yongchuan Hospital Affiliated to Chongqing Medical University from June 2017 to December 2019 were selected as the research objects. According to the random number table method, the patients were divided into control group and observation group, with 70 patients in each group. Patients in the control group were orally inhaled Salbutamol Sulphate Aerosol, 0.1 mg/time, four times daily. Patients in the observation group were po administered with Pingchuan Kangyan Capsules on the basis of control group, 2 grains/time, three times daily. Both groups were treated consecutively for 8 weeks. The clinical efficacy of two groups were observed, and the symptom improvement, FEV1, FEV1 predicted value, PEF, and the levels of ICAM-1, TGF-β1, and IL-17 were compared. Results After treatment, the total effective rate was 94.29% in the observation group, which was significantly higher than 82.86% in the control group (P<0.05). After treatment, the time of antitussive, expectoration disappear, and wheezing disappear in the observation group were significantly shorter than those in the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment, FEV1, FEV1 predicted value, and PEF levels in two groups were significantly increased (P<0.05), while FEV1, FEV1 predicted value, and PEF in the observation group were significantly higher than those in the control group (P<0.05). After treatment, the levels of ICAM-1, TGF-β1, and IL-17 in two groups were significantly decreased (P<0.05), and the levels of ICAM-1, TGF-β1, and IL-17 were significantly lower than those in the control group (P<0.05). Conclusion Pingchuan Kangyan Capsules combined with salbutamol has a good clinical effect in treatment of bronchial asthma, which can effectively reduce inflammation and improve lung function, it has good clinical research value.

R974